Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413457 | 0.83 | L3MBTL1 (0.62) | L3MBTL1CREBBPTSHRCYP19A1ADORA2A | |
| SCHEMBL9908393 | 0.81 | L3MBTL1 (0.61) | L3MBTL1CREBBPALDH1A1CYP19A1ADORA2A | |
| SCHEMBL10085530 | 0.81 | L3MBTL1 (0.61) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL3763491 | 0.81 | L3MBTL1 (0.61) | L3MBTL1CREBBPTSHRCYP19A1ADORA2A | |
| SCHEMBL1244019 | 0.81 | L3MBTL1 (0.61) | L3MBTL1CREBBPTSHRCYP19A1ADORA2A | |
| SCHEMBL31420605 | 0.80 | L3MBTL1 (0.59) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL21492606 | 0.80 | L3MBTL1 (0.59) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| SCHEMBL671242 | 0.79 | TSHR (0.63) | L3MBTL1CREBBPTSHRALDH1A1CYP19A1 | |
| SCHEMBL31420829 | 0.79 | L3MBTL1 (0.57) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 | |
| SCHEMBL13181030 | 0.79 | L3MBTL1 (0.57) | L3MBTL1CREBBPCYP19A1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | disclosed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-110234656-A | Extracellular nucleotides enzyme inhibitor and its application method | 卡利泰拉生物科技公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-3510040-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | L3MBTL1 4421/4885CREBBP 3037/4885TSHR 2898/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | L3MBTL1 4479/4885CREBBP 3281/4885TSHR 2768/4885 |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | L3MBTL1 4479/4885CREBBP 3281/4885TSHR 2768/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | L3MBTL1 4683/4885CREBBP 3222/4885TSHR 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.